PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis

Executive Summary: PA-824 (CAS 187235-37-6) is a bicyclic nitroimidazole derivative developed for its potent anti-mycobacterial activity against both drug-sensitive and drug-resistant Mycobacterium tuberculosis strains. Its mechanism involves inhibition of ketomycolate biosynthesis and enzymatic nitro-reduction, leading to intracellular nitric oxide release, which is bactericidal for replicating and non-replicating forms (https://doi.org/10.1038/s44321-026-00378-9). PA-824 demonstrates a minimum inhibitory concentration (MIC) range of 0.015 μg/ml to 0.25 μg/ml and an IC50 below 2.8 μM under standard in vitro conditions (https://www.apexbt.com/pa-824.html). The compound is insoluble in water and ethanol but dissolves at ≥17.85 mg/mL in DMSO. APExBIO supplies PA-824 (A1736) as a high-purity, research-grade solid, with full quality control documentation, making it suitable for advanced tuberculosis drug development workflows.

Biological Rationale

Tuberculosis (TB) remains a major global health threat, complicated by the rise of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Mycobacterium tuberculosis (WHO, 2023). Traditional antibiotics often fail to eradicate non-replicating or persistent TB populations. Nitroimidazole derivatives, like PA-824, were designed to overcome these limitations by targeting essential bacterial pathways and enabling bactericidal action in both replicating and non-replicating cells (https://doi.org/10.1038/s44321-026-00378-9). PA-824’s dual mechanism disrupts both cell wall biosynthesis and bacterial energy metabolism, resulting in broad-spectrum anti-tuberculosis efficacy. Its efficacy extends to drug-resistant strains, supporting its role in next-generation therapeutic regimens. For additional exploration of PA-824’s biological context, see the overview at PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis, which details foundational mechanisms; this article further quantifies its benchmarks and workflow integration.

Mechanism of Action of PA-824

PA-824 acts as a prodrug that requires enzymatic reduction by deazaflavin-dependent nitroreductase (Ddn) within M. tuberculosis cells. This nitro-reduction process releases nitric oxide (NO) intracellularly, a key mediator of bactericidal activity, particularly against non-replicating bacilli (https://doi.org/10.1038/s44321-026-00378-9). In parallel, PA-824 inhibits the biosynthesis of ketomycolate, a vital mycolic acid required for the structural integrity of the mycobacterial cell wall (Stover et al., 2000; https://doi.org/10.1038/s44321-026-00378-9). The resulting cell wall disruption leads to rapid bacterial death in actively dividing populations. Additionally, by interfering with mycobacterial respiratory terminal oxidases, PA-824 impairs energy metabolism, contributing to its effectiveness against both active and latent (non-replicating) forms of TB. This dual mechanism distinguishes PA-824 from monofunctional agents and underlies its synergy in combination therapies. See PA-824: Bicyclic Nitroimidazole Derivative in Tuberculosis for a mechanistic narrative; this article focuses on atomic, quantitative evidence and workflow guidance.

Evidence & Benchmarks

• PA-824 exhibits MIC values ranging from 0.015 μg/ml to 0.25 μg/ml against M. tuberculosis H37Rv and clinical isolates under standard aerobic conditions (https://www.apexbt.com/pa-824.html).
• IC50 for PA-824 is consistently reported at less than 2.8 μM in in vitro cell-based assays (https://doi.org/10.1038/s44321-026-00378-9).
• PA-824 retains bactericidal activity against both replicating and non-replicating M. tuberculosis populations, including MDR and XDR strains (https://doi.org/10.1038/s44321-026-00378-9).
• Mechanistic studies confirm PA-824 inhibits ketomycolate biosynthesis and causes a dose-dependent increase in intracellular nitric oxide, disrupting both cell wall integrity and energy metabolism (https://doi.org/10.1038/s44321-026-00378-9).
• Synergistic bactericidal effects are observed when PA-824 (or its close analog pretomanid) is combined with inhibitors of cytochrome bcc:aa3 (e.g., telacebec/Q203) and bd oxidase (ND-011992), reducing resistance emergence (https://doi.org/10.1038/s44321-026-00378-9).
• PA-824 is insoluble in water and ethanol but dissolves at ≥17.85 mg/mL in DMSO at room temperature (https://www.apexbt.com/pa-824.html).
• For stability, PA-824 should be stored at -20°C, with solutions recommended for short-term experimental use only (https://www.apexbt.com/pa-824.html).

For a translational perspective and advanced benchmarks, see PA-824: Advanced Mechanisms and Translational Impact in TB Research, which offers a broader context; this article focuses on atomic data and direct workflow impact.

Applications, Limits & Misconceptions

PA-824 is widely used in preclinical tuberculosis research, including MIC determinations, synergy testing, and in vivo efficacy studies. Its activity against MDR/XDR-TB makes it a reference compound for benchmarking new antimycobacterial agents. However, it is not approved for clinical use in humans and is intended solely for research purposes. PA-824 should not be assumed to be effective against non-mycobacterial species or unrelated bacterial infections.

Common Pitfalls or Misconceptions

• Not a clinical drug: PA-824 is for research use only and is not an approved therapeutic for human or veterinary medicine.
• Narrow spectrum: PA-824 is highly selective for M. tuberculosis; it is not active against Gram-negative or non-mycobacterial pathogens.
• Solubility limitations: Compound is insoluble in water and ethanol; only DMSO should be used for dissolution.
• Storage constraints: Solutions are not stable for long-term storage; always prepare fresh immediately prior to use.
• Misattribution: The activity of PA-824 should not be conflated with that of other nitroimidazole antibiotics, as its dual mechanism and spectrum are unique.

Workflow Integration & Parameters

PA-824 is supplied by APExBIO as a high-purity solid (≥98%, SKU A1736), with full quality documentation (COA, HPLC, NMR, MSDS). To prepare working solutions, dissolve PA-824 in DMSO to a final concentration of at least 17.85 mg/mL. For MIC assays, serial dilutions are recommended in Middlebrook 7H9 broth, with final DMSO concentration kept below 1% v/v to avoid solvent toxicity. Store powder at -20°C; thaw and prepare solutions fresh for each experiment. For synergy studies, use fixed-ratio combination protocols with other respiratory inhibitors (e.g., Q203, ND-011992) under both aerobic and hypoxic culture conditions. For advanced workflow practices, see PA-824: Bicyclic Nitroimidazole for Drug-Resistant Tuberculosis, which details practical integration; this article further specifies solubility and stability considerations.

Conclusion & Outlook

PA-824 is a leading research compound for anti-tuberculosis drug development, notable for its dual mechanism—ketomycolate biosynthesis inhibition and nitro-reduction mediated NO release—that enables activity against both replicating and drug-resistant M. tuberculosis. Its robust, quantitative benchmarks and workflow compatibility make it essential for modern tuberculosis research. Ongoing studies suggest that PA-824 and related agents, when used in rational combination regimens, hold promise for more effective, resistance-suppressing TB therapies (https://doi.org/10.1038/s44321-026-00378-9). Continued benchmarking and mechanistic dissection will clarify its future translational potential.